Sheila Clancy
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
HIV Research and Treatment, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, Cardiomyopathy and Myosin Studies, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Clinical targeting of HIV capsid protein with a long-acting small molecule(2020)403 cited
- → Differential Regulation of WASP and N-WASP by Cdc42, Rac1, Nck, and PI(4,5)P2(2007)136 cited
- → High-Throughput Kinetic Screening of Hybridomas to Identify High-Affinity Antibodies Using Bio-Layer Interferometry(2014)50 cited
- → Highly selective inhibition of myosin motors provides the basis of potential therapeutic application(2016)40 cited
- → Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide(2019)35 cited
- → Functional Label-Free Assays for Characterizing the in Vitro Mechanism of Action of Small Molecule Modulators of Capsid Assembly(2015)11 cited
- → Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure Prophylaxis(2025)3 cited
- → The Small Molecule Smooth Muscle Myosin Inhibitor, CK-2018571, Selectively Inhibits ATP Hydrolysis and Relaxes Smooth Muscle In Vitro(2010)1 cited
- → Characterization of a Long Acting Smooth Muscle Myosin Inhibitor, CK‐2125927, as a Novel Therapeutic Mechanism for Bronchodilation(2011)
- → A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology(2025)